Written question asked by Ian Murray (Labour) on Wednesday, 13 March 2024, in the House of Commons. It was due for an answer on Friday, 22 March 2024 (named day). It was answered by Andrew Griffith (Conservative) on Friday, 22 March 2024 on behalf of the Department for Science, Innovation and Technology.
Advanced Therapy Medicinal Products: Scotland
- Question
-
To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to help support research into cell and gene therapy in Scotland.
- Answer
-
The UK is a world-leader in the development and manufacture of cell and gene therapies thanks to government investment in innovation and skills, including through the Cell and Gene Therapy Catapult (CGTC).
DSIT also invested £10 million - alongside £10 million from Scottish Enterprise – to support a new Oligonucleotide Manufacturing Innovation Centre of Excellence in Glasgow.
The Vaccine Taskforce provided funding for a state-of-the art CGTC facility in Braintree to accelerate the development and manufacturing of advanced therapies at clinical and commercial scale.
My department also supported CGTC to establish apprenticeships and training programmes to upskill people across the UK.
Secondary information
- Type
- Written question
- Reference
- 18416
- Session
- 2023-24
- Subjects
- Scotland Research Advanced therapy medicinal products
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-03-22 22:22:23 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2023-24/18416
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2023-24/18416
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2023-24/18416